Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule
Idag, 17:29
11:29 AM EDT, 04/20/2026 (MT Newswires) -- Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.
Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.
Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.
Shares of the company were down more than 6% in Monday's trading.
Price: 0.38, Change: -0.03, Percent Change: -6.47
Ämnen i artikeln
Cosmos Health Completes Phase 1 Execution of Liv18 Ahead of Schedule
Idag, 17:29
11:29 AM EDT, 04/20/2026 (MT Newswires) -- Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.
Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.
Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.
Shares of the company were down more than 6% in Monday's trading.
Price: 0.38, Change: -0.03, Percent Change: -6.47
Ämnen i artikeln
Banker
Analys
Banker
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
-160x160.jpg&w=3840&q=75)
